<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00135759</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-15469-1</org_study_id>
    <secondary_id>R21-15469-1</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00135759</nct_id>
  </id_info>
  <brief_title>Addition of Naltrexone to Methadone Taper</brief_title>
  <official_title>Place of Low-Dose Naltrexone in Opiate Detoxification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a continuing search for more effective opiate detoxification treatments. This&#xD;
      study's purpose is to investigate the effects of adding very low doses of naltrexone to a&#xD;
      methadone tapering treatment in opioid dependent individuals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although many different techniques for opiate detoxification exist, the search continues for&#xD;
      more effective approaches to reduce the duration and discomfort associated with opioid&#xD;
      withdrawal. It has been shown that very low doses of naltrexone administered in the presence&#xD;
      of opiates has analgesic and dependency reducing properties. The purpose of this study is to&#xD;
      investigate the effects of very low doses of naltrexone administered during a methadone&#xD;
      tapering schedule for opiate detoxification. In addition, this study will compare the&#xD;
      effectiveness of two different dose regimens of naltrexone.&#xD;
&#xD;
      Participants in this double-blind study will be recruited among opioid dependent individuals&#xD;
      already enrolled in a 6-day inpatient opioid detoxification program. Participants will be&#xD;
      already receiving standard treatment to control discomfort during a methadone tapering&#xD;
      schedule. Participants will be randomly assigned to one of three groups. Two of the groups&#xD;
      will be given naltrexone; Group 1 will receive 0.125 mg each day, and Group 2 will receive&#xD;
      0.250 mg each day. Group 3 will receive a placebo. Participants will be evaluated upon&#xD;
      enrollment for opiate addiction severity. They will continue to be evaluated daily for signs&#xD;
      of withdrawal and salivary cortisol. An additional evaluation and urine test will be&#xD;
      completed 1 day following discharge. Daily evaluations will take 15 minutes to complete.&#xD;
      Seven days following discharge, participants will be contacted for a 20-minute phone&#xD;
      interview. During the phone interview, participants will schedule an appointment to provide a&#xD;
      final urine specimen for the detection of drugs of abuse.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Withdrawal intensity</measure>
    <time_frame>6 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retention in treatment</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>Heroin Dependence</condition>
  <condition>Opioid-Related Disorders</condition>
  <condition>Substance-Related Disorders</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>experimental</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>experimental</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>low dose naltrexone in addition to daily methadone taper</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo comparator</intervention_name>
    <description>1 capsule/day for 6 days</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naltrexone</intervention_name>
    <description>0.125 mg capsule/day for 6 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naltrexone</intervention_name>
    <description>0.250 mg capsule/day for 6 days</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Current DSM-IV diagnosis of opiate dependence&#xD;
&#xD;
          -  Reads and understands English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious medical disorders (e.g., uncontrolled hypertension, acute or chronic active&#xD;
             hepatitis, kidney failure, uncontrolled diabetes)&#xD;
&#xD;
          -  Psychiatric conditions that require intensive services (e.g., depression with suicidal&#xD;
             ideation, psychosis)&#xD;
&#xD;
          -  Mental retardation or other disorder that might limit ability to give informed consent&#xD;
&#xD;
          -  Pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Mannelli, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>August 23, 2005</study_first_submitted>
  <study_first_submitted_qc>August 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2005</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <name_title>Paolo Mannelli, M.D.</name_title>
    <organization>Duke University</organization>
  </responsible_party>
  <keyword>opiate dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Heroin Dependence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

